DraftUnitedHealthcarePolicy CS151NE.D

Carrier Testing Panels for Genetic Diseases (for Nebraska Only)

Defines medical policy for carrier genetic screening panels used for reproductive carrier screening in Nebraska, including which panel sizes/indications are considered medically necessary and which are not. Applies to providers and coverage determinations in the State of Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyCarrier Testing Panels for Genetic Diseases (for Nebraska Only)

Policy CodePolicy CS151NE.D

Change TypeRevised definitions and clarified society guidance

Effective DateJul 1, 2025

Next Review Date

Key ActionDocument pre-test genetic counseling and confirm panel size/indication meet coverage criteria before ordering.

SourceLink

POLICY UPDATE CHANGES

Updated definition of 'Gene Panel' and updated supporting sections including Clinical Evidence, FDA, and References.

ACOG Practice Advisory updated hemoglobinopathy testing recommendation to offer testing to all individuals planning a pregnancy or at first prenatal visit rather than race/ethnicity-based testing.

≤6Proven medically necessary for reproductive carrier screening

7–15Proven when Ashkenazi Jewish ancestry or affected relative

≥16Unproven / not medically necessary

CFTR, SMN1Recommended genes to include

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

NebraskaGeographic application

Coverage Criteria

Reproductive Carrier Screening — Covered criteria

Covered when the following conditions are met:

Panel size ≤6: Reproductive Carrier Screening Panels of up to six genes are proven and medically necessary.≤ 6 genes

Source: policy statement on proven medically necessary panel sizes.

Panel size 7–15 with medical indication: Reproductive Carrier Screening Panels of up to 15 genes are proven and medically necessary when an individual and/or their reproductive partner meets at least one of the following: (1) Ashkenazi Jewish ancestry (individual or reproductive partner has at least one parent or grandparent of Ashkenazi Jewish descent); OR (2) a biological first- or second-degree relative has been affected by one or more of the conditions evaluated by the panel.7–15 genes plus AJ ancestry OR affected relative

Source: policy statement specifying eligibility for 7–15 gene panels.

Not medically necessary / Unproven

Panels ≥16 genes: Reproductive Carrier Screening Panels comprised of 16 or more genes are unproven and not medically necessary due to insufficient evidence of efficacy.≥ 16 genes

Source: policy exclusion for large panels.

Carrier screening for other indications: Carrier screening for all other indications (non-reproductive indications) is unproven and not medically necessary.other indications

Source: policy statement on non-reproductive indications.

Evidence considerations

Evidence summaries relevant to coverage decisions:

Performance and validity: Studies report variable detection rates (DR) and recurrence risk (RR) across laboratories and panels; ClinGen curation found most ECS panel conditions had definitive gene-disease associations (203/208), but inter-laboratory differences in methods and variant selection affect DR/RR and comparability.

Leung et al.; Balzotti et al.; methodological limitations noted.

Comparative utility vs ethnicity-based screening: Large cohort studies demonstrate that expanded pan-ethnic panels identify substantially more carriers and carrier couples than ethnicity-based or guideline-limited panels (e.g., 29.4% carrier rate with a 102-gene ECS vs 8.5% ethnicity-based), reducing missed carriers in admixed populations.

Peyser et al., Rosenblum/Haque results.

Equity considerations: Self-reported ethnicity is unreliable; reliance on it can miss carriers—supporting pan-ethnic approaches to improve equitable detection across diverse populations.

Shraga and other analyses noted discrepant ancestry reporting and missed carriers.

Society Recommendations for Offering ECS

Professional society recommendations and conditions to consider when offering ECS

ACOG general recommendations: Offer hemoglobinopathy testing to all individuals planning a pregnancy or at the first prenatal visit if no prior testing has been performed; offer carrier screening for cystic fibrosis and spinal muscular atrophy to all individuals who are pregnant or considering pregnancy. If expanded carrier screening is considered, consensus criteria include: disorder carrier frequency >1/100, well-defined phenotype with early onset and detrimental impact on quality of life, availability of prenatal diagnosis/management, and exclusion of adult-onset conditions.

ACOG Practice Advisories and Committee Opinions.

ACMG tier recommendations: Adopt a tiered approach: Tier 1 = CF + SMA + risk-based; Tier 2 ≥1/100 carrier frequency; Tier 3 ≥1/200 carrier frequency (includes X-linked) and Tier 3 should be offered to all pregnant patients and those planning pregnancy; Tier 4 (<1/200) considered for consanguinity or specific family history.

ACMG Practice Resource (Gregg et al., 2021).

NSGC guidance: NSGC recommends that ECS may be offered to all individuals considering reproduction, pregnant individuals, and their partners; the recommendation is conditional, emphasizes shared decision-making, access to counseling, and addressing barriers such as insurance coverage and access to genetics professionals.

Reproductive Carrier Screening Panels comprised of 16 or more genes are considered unproven and not medically necessary due to insufficient evidence of efficacy. This policy basis is drawn from the coverage criteria that define panels up to six genes as proven and panels of 7–15 genes as conditionally proven when eligibility requirements are met, and explicitly lists panels ≥16 genes as excluded.

When ordering or billing, panels that include ≥ 16 genes may be subject to denial as not medically necessary; providers should ensure the requested panel meets covered size and eligibility criteria or document clinical justification aligned with the policy.

Within the sections addressing exclusions and not-medically-necessary determinations, the document does not enumerate other specific test types or clinical indications that are explicitly excluded from coverage. The policy notes general limitations of the evidence base and focuses exclusions on panel size and non-reproductive indications rather than listing additional named tests.

Because no other explicit exclusions are stated in these sections, coverage decisions beyond panel size and reproductive versus non-reproductive indication should be informed by the member's benefit plan and the policy's stated clinical criteria.

Per ACOG guidance referenced in the policy, carrier screening panels should not include adult-onset conditions. ACOG recommends that conditions included in expanded carrier screening have early onset and clinically significant phenotypes and specifically advises against inclusion of adult-onset disorders on routine carrier panels.

Providers and laboratories should review panel content to confirm adult-onset conditions are not reported as part of routine reproductive carrier screening, and interpretation should involve clinicians with genetics expertise as noted by professional guidance.

Carrier screening performed for indications outside of the reproductive context described in this policy (preconception or prenatal testing to identify carriers and at-risk couples) is considered unproven and not medically necessary. The policy explicitly lists "Carrier Screening for all other indications" among services deemed not medically necessary.

Requests for carrier testing for non-reproductive clinical reasons should therefore be evaluated against the member's benefit plan and may be denied under this policy unless other plan provisions or medical necessity criteria apply.

The evidence reviewed in this policy is predominantly observational and heterogeneous; reviewers noted significant methodological limitations across studies, inconsistent methodologies and populations, and many studies rated poor or very poor quality. These limitations constrain definitive conclusions about clinical utility and comparative outcomes.

The policy highlights the need for standardized reporting of detection rate and recurrence risk metrics and cautions that variability in laboratory methods and reporting can affect the reliability of carrier detection estimates used for reproductive decision-making.

The Royal College of Obstetricians and Gynaecologists (RCOG) concludes there is insufficient evidence to recommend routine testing of all prospective parents. RCOG supports targeted preconception screening for individuals at high risk and emphasizes the lack of standardization among available expanded carrier screening panels.

RCOG further recommends that providers understand the specific panel content before interpreting results and that interpretation be performed by clinicians with appropriate genetics expertise.

Covered Indications

Reproductive carrier screening (preconception or prenatal) for autosomal recessive and X-linked disorders — panels up to 6 genes proven; up to 15 genes proven when AJ ancestry or affected first/second-degree relative.

Panel sizing and eligibility: Reproductive carrier screening panels of up to six genes are medically necessary for reproductive screening; panels up to 15 genes are medically necessary when the individual or partner has Ashkenazi Jewish ancestry or a first- or second-degree relative affected by a condition on the panel. Panels of 16 or more genes are considered unproven and not medically necessary.≤6 genes; 7–15 genes with AJ ancestry or affected relative; ≥16 genes not covered

Policy coverage rules align with society guidance on core conditions (CF, SMA) and documented eligibility requirements.

Counseling and informed decision-making: Pre-test genetic counseling is strongly recommended prior to ordering carrier screening to discuss advantages, limitations, and implications of testing; documentation of counseling is implied as best practice.

ACOG and NSGC emphasize counseling; policy recommends counseling as best practice.

Eligibility Requirements

Coverage for reproductive carrier screening panels larger than six genes but up to 15 genes is conditional: the individual being tested or their reproductive partner must have either (1) documented Ashkenazi Jewish ancestry (at least one parent or grandparent of Ashkenazi Jewish descent) or (2) a biological first- or second-degree relative affected by one or more of the conditions evaluated by the panel.

When these eligibility requirements are met, panels of 7–15 genes are considered proven and medically necessary under this policy; documentation of ancestry or family history should be provided to support coverage determinations.

No top-level eligibility nodes are specified in this section.

Not Covered

Not covered under this policy are reproductive carrier screening panels comprised of 16 or more genes, which are designated as unproven and not medically necessary. Additionally, carrier screening performed for non-reproductive indications is considered not medically necessary.

Providers ordering panels that meet these exclusion criteria should anticipate potential claim denial and ensure testing aligns with the defined covered indications and panel-size thresholds.

This portion of the policy does not provide a list of specific tests or clinical indications that are separately and explicitly excluded from coverage beyond the panel-size and indication-based exclusions already stated.

Coverage determinations for tests not explicitly addressed should be made in the context of the member's federal, state, or contractual benefit plan and the policy's described medical necessity criteria.

Consistent with RCOG's 2024 scientific impact paper, the policy notes that routine universal expanded carrier screening (ECS) of all prospective parents is not supported by current evidence. As such, routine universal ECS is not a covered standard under this guidance.

The RCOG stance supports targeted screening of individuals at higher risk and emphasizes panel standardization and genetics expertise for interpretation rather than endorsing universal population-based ECS.

Coding

Applicable procedure codes (reference)CPT

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders (e.g., Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1.
81443	Genetic testing for severe inherited conditions (e.g., cystic fibrosis, Ashkenazi Jewish-associated disorders [e.g., Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (e.g., ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH).
81479	Unlisted molecular pathology procedure

Covered CPT Codesmixed

No codes listed

Carrier frequency thresholds referenced

ACOG conservative thresholdACOG suggests panels target disorders with carrier frequency ≥ 1/100 (correlates with disease incidence ~1/40,000).

ACMG tier referenceACMG Tier 3 includes conditions with carrier frequency ≥ 1/200 (Tier 2 ≥1/100; Tier 4 <1/200).

Study-derived thresholdsJohansen Taber et al. identified 37 conditions meeting a conservative ≥1/100 threshold and 74 meeting ≥1/200 in a 176-condition analysis.

ACOG‑proposed carrier frequency inclusion (≥ 1/100)

ACOG proposed inclusion criterionDisorders included in ECS panels should have a carrier frequency of 1/100 or greater, with well-defined phenotype and detrimental impact on quality of life.

Rationale

Provider Actions & Billing Considerations

Billing Rule

Code considerations

Use of the listed procedure codes may be subject to medical necessity review consistent with policy criteria (panel size and indications). Listing of a code does not guarantee coverage or payment; check the member's benefit plan and applicable coding guidance before billing.

Affected codes may include: 0400U, 81412, 81443, 81479

Prior Authorization

Check plan-specific prior authorization

Prior authorization is not specified in this policy section; however, coverage determinations may vary by federal, state, or contractual benefit plan. Verify plan-specific prior authorization requirements before ordering testing.

Check the member's benefit plan for prior authorization rules and procedures

Background

Carrier screening identifies asymptomatic individuals who may carry variants for autosomal recessive or X-linked disorders that could affect offspring; next-generation sequencing and panel-based approaches enable simultaneous analysis of multiple genes. Professional bodies (ACOG, ACMG, NSGC) recommend screening for cystic fibrosis (CFTR), spinal muscular atrophy (SMN1), and hemoglobinopathies for individuals who are pregnant or planning pregnancy.

This policy defines covered reproductive carrier screening by panel size and context: panels of ≤6 genes are supported as medically necessary; panels of 7–15 genes may be covered when eligibility requirements are met (for example, Ashkenazi Jewish ancestry or a biologic first- or second-degree relative affected by a condition on the panel); panels of ≥ 16 genes are categorized as unproven and not medically necessary. Pre-test genetic counseling is strongly recommended, and providers should document counseling and confirm that the selected panel aligns with guideline-based criteria and the member's benefit plan.

Definitions

Carrier Screening definition

DefinitionGenetic testing performed on an asymptomatic individual to determine whether they carry a variant associated with a genetic disorder that could be passed to biological children.

PurposeIdentify carriers of autosomal recessive or X‑linked conditions to inform reproductive decision-making.

Typical useOffered preconception or prenatally to individuals planning pregnancy, pregnant individuals, and reproductive partners per guideline recommendations.

First-/Second-Degree Relative definitions

First‑Degree RelativeIncludes parents, siblings, and children.

Second‑Degree RelativeIncludes half‑siblings, aunts/uncles, grandparents, grandchildren, nieces/nephews.

Ordering & Interpretation Guidance

Documentation Required

Recommend and document pre‑test genetic counseling

Pre‑test genetic counseling is strongly recommended and should be documented as part of the ordering process; record counseling content and that counseling occurred.

Document that pre‑test counseling occurred and summarize the information discussed (advantages, limitations, potential outcomes).
Include counseling notes when submitting claims or prior authorization requests if applicable.

Documentation Required

Document counseling as part of the ordering process

Include documentation of genetic counseling in the order or medical record when requesting carrier screening to support medical necessity and informed decision‑making.

Document counseling in the ordering process or test requisition where possible.
Counseling documentation can help demonstrate alignment with coverage criteria.

Revision History

2025-07-01policy_revisionLatest

Updated definition of 'Gene Panel' and updated Clinical Evidence, FDA, and References sections; archived previous policy version CS151NE.C.

Policy Summary

PayerUnitedHealthcare

PolicyCarrier Testing Panels for Genetic Diseases (for Nebraska Only)

Policy CodePolicy CS151NE.D

Change TypeRevised definitions and clarified society guidance

Effective DateJul 1, 2025

Next Review Date

Key ActionDocument pre-test genetic counseling and confirm panel size/indication meet coverage criteria before ordering.

SourceLink

On This Page

Clinical impact: ECS results have been shown to influence reproductive planning and prenatal diagnostic uptake (e.g., a majority of preconception at-risk couples pursued options to avoid affected births; prenatal ARCs pursued diagnostic testing with some terminations), though prospective comparative outcome data are limited and many studies are observational.

Johansen Taber et al.; other cohort studies report behavior changes.

Implementation/resource impact: Large-panel or genomic sequencing-based screening increases counseling and workflow burden (e.g., median 64 minutes genetic counselor prep time for positive results) and raises challenges in standardization and result interpretation.

NextGen/Wilfond and other implementation reports.

NSGC evidence-based practice guideline (Sagaser et al.).

RCOG stance: RCOG concludes there is insufficient evidence to recommend routine testing of all prospective parents; targeted screening for high-risk individuals is appropriate, panels lack standardization, and interpretation should be by clinicians with genetics expertise.

RCOG scientific impact paper (Elson et al., 2024).

Preconception or prenatal carrier screening to identify carriers and at-risk couples

Preconception or prenatal carrier screening to identify carriers and at-risk couples — evidence that ECS influenced reproductive planning and prenatal decision-making.

Preconception impact: In preconception cohorts of at-risk couples identified by ECS, a majority reported planning or pursuing pregnancy management options to avoid having an affected child (e.g., 77% of preconception ARCs in Johansen Taber et al.).

Johansen Taber et al. survey of ARCs from a 176-condition ECS panel.

Prenatal impact: Among couples who received ECS results during pregnancy, a proportion pursued prenatal diagnostic testing and some affected pregnancies resulted in termination (e.g., in Johansen Taber et al., 37% pursued PNDx; 36% of those had affected pregnancies, 40% of which resulted in termination).

Johansen Taber et al.; other cohorts report increased prenatal diagnostic uptake.

Detection and carrier rates: Large ECS panels identify substantially more carriers than limited panels (e.g., in a 102-gene panel study 29.4% were carriers; in a 274-gene panel 63.8% had at least one finding), increasing identification of at-risk couples but also detecting many carriers of varying clinical significance.

Peyser et al.; large-panel prevalence data.

Study limitations: Observed changes in reproductive behavior support clinical impact, but many studies are observational with methodological limitations, inconsistent laboratory methods, and limited prospective outcome data to quantify long-term benefits, warranting cautious interpretation of utility evidence.

Leung et al.; evidence quality concerns noted across studies.

Individuals planning pregnancy, pregnant individuals, and their reproductive partners for carrier screening of CF, SMA, hemoglobinopathies, and other conditions per tiered/consensus criteria.

Primary target populations: Individuals planning pregnancy, pregnant individuals, and their reproductive partners should be offered carrier screening for cystic fibrosis (CFTR), spinal muscular atrophy (SMN1), hemoglobinopathies, and other conditions according to tiered or consensus criteria from professional societies.

ACOG recommends CF, SMA, hemoglobinopathy testing for all pregnant or planning-pregnancy individuals; policy strongly recommends inclusion of CFTR and SMN1.

ACOG links the ≥1/100 carrier frequency to meaningful disease incidence (≈1/40,000) and to evidence-based panel composition.

Clinical validity supportClinGen curation work found the majority of ECS panel conditions meet strong gene–disease association criteria, supporting ACOG inclusion criteria.

Carrier frequency thresholds mentioned by professional societies (ACOG/ACMG tiers)

ACMG tier definitionsTier 1: CF + SMA + risk-based; Tier 2: ≥1/100 (includes Tier 1); Tier 3: ≥1/200 (includes Tier 2 and X‑linked); Tier 4: <1/200 (includes Tier 3).

ACOG consensus criterionACOG recommends disorders included in ECS panels generally have carrier frequency >1/100 and meet severity/onset/diagnosability criteria.

Use guidanceACMG recommends offering Tier 3 screening to all pregnant patients and those planning pregnancy; Tier 4 reserved for consanguinity or specific history.

UnitedHealthcare may use third‑party tools (e.g., InterQual) to assist in benefit administration

Documentation Required

Pre-test genetic counseling recommended

Pre-test genetic counseling is strongly recommended to inform persons being tested about the advantages and limitations of carrier screening and to improve the accuracy of ethnicity/family‑history information used for test selection and risk calculation.

Document that genetic counseling was provided or offered prior to testing when applicable
Genetic counseling may help clarify self‑reported ethnicity and family history for accurate test selection

Documentation Required

Ethnicity documentation and testing choice

Self-reported ethnicity may be unreliable for clinical decision-making. Consider pan‑ethnic (expanded) carrier screening approaches or document detailed family history/genetic ancestry when selecting targeted panels.

If relying on ethnicity to select a panel, document how ethnicity was obtained (self-report vs. genetic ancestry)
Consider pan‑ethnic panels when ancestry is unknown, unclear, or admixed

Documentation Required

Documentation of benefit alignment

Document alignment with the member's benefit plan requirements when ordering or billing for carrier screening. In the event of a conflict, federal, state, or contractual benefit plan provisions govern coverage.

Include in the record: clinical indication, family history/ancestry information, genetic counseling notes, and how the selected panel meets policy criteria (panel size, indications)
If a panel exceeds the covered gene count (see policy criteria), document the rationale and obtain prior authorization where plan allows

Denial Risk

Panel size limits and denial risk

Panels of 16 or more genes are considered unproven and not medically necessary under this review; such panels may be denied. Reproductive carrier screening panels of up to 6 genes are proven, and panels up to 15 genes are proven when specific criteria are met (e.g., Ashkenazi Jewish ancestry or an affected first‑ or second‑degree relative).

Panels ≥16 genes: may be denied as not medically necessary
Panels ≤6 genes: generally covered when clinically indicated
Panels 7–15 genes: covered only when policy clinical criteria are met (document ancestry or relevant family history)

Step Therapy

Step therapy / sequencing

No step therapy or sequencing requirements are described in this evidence review.

Not applicable: no step therapy specified

Note

Benefit plan governs coverage

This policy assists in interpreting UnitedHealthcare standard benefit plans but does not replace checking the specific member benefit documents. Use federal, state, or contractual benefit plan terms where they differ from this policy.

When in doubt, reference the member's contract for coverage determination
UnitedHealthcare reserves the right to modify policies and may use third‑party criteria in administration

Policy useCoverage for panels up to 15 genes may require a biological first‑ or second‑degree relative affected by a condition evaluated by the panel.

Expanded carrier screening (ECS) definition

DefinitionMultigene, pan‑ethnic testing panels that screen many autosomal recessive and X‑linked conditions (reported panel sizes up to 274 genes) to identify carriers and at‑risk couples.

Contrast to ethnic panelsECS is pan‑ethnic rather than limited to a single ancestry and can detect carriers missed by ethnicity‑based testing.

Observed panel sizesLiterature describes ECS panels ranging from tens to hundreds of genes (examples: 87, 102, 176, 208, 274 genes).

Detection rate (DR) and recurrence risk (RR) definitions

Detection rate (DR)Metric calculated from summed disease allele frequencies to estimate how frequently pathogenic variants are detected by a laboratory's testing method (affected by lab methods and variant selection).

Recurrence risk (RR)Estimated reproductive risk derived from DR and allele frequencies to inform likelihood of an affected pregnancy for a given pairing.

Sources of variabilityDR and RR vary across laboratories due to differences in calculation methods, variant selection, and technical challenges of NGS, affecting counseling and residual risk estimates.

ACMG Tiered Carrier Screening definition

ACMG tiered approachTiered approach: Tier 1 = CF + SMA + risk‑based; Tier 2 = ≥1/100 carrier frequency (includes Tier 1); Tier 3 = ≥1/200 carrier frequency (includes Tier 2 and X‑linked); Tier 4 = <1/200 carrier frequency (includes Tier 3).

Offer recommendationsACMG recommends offering Tier 3 carrier screening to all pregnant patients and those planning pregnancy; Tier 4 considered for consanguinity or specific history.

Terminology guidanceACMG suggests using the term 'carrier screening' rather than 'expanded carrier screening' and promoting population‑neutral paradigms.

Note

Consider appropriate referring clinicians

Be aware that patients in studies were referred by fertility specialists, OB/GYNs, and genetic counselors; involve appropriate referring clinicians when applicable.

Referral sources in the literature included fertility specialists, obstetricians/gynecologists, and genetic counselors.
Use appropriate specialty consultation (genetics) for interpretation and counseling as needed.

Note

No specified ordering restriction; ensure qualified interpretation

There is no explicit restriction on who may order carrier screening in the sections reviewed; ensure interpretation is performed by clinicians with appropriate genetics expertise.

No explicit ordering restriction is provided in these sections.
Interpretation should be by clinicians with appropriate knowledge of clinical genetics.